Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons

Experimental Neurology

Volumn 188, Issue 2, 2004, Pages 461-470

  Darvesh, Sultan ^a,b,c,e   Arora, Rakesh C ^a   Martin, Earl ^b   Magee, David ^c   Hopkins, David A ^a   Armour, J Andrew ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MOUNT SAINT VINCENT UNIVERSITY   (Canada)

^c UNIVERSITY OF NEW BRUNSWICK   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

( ) Huperzine A; Acetylcholine; Acetylcholinesterase; Butyrylcholinesterase; Donepezil; Galantamine; Metrifonate; Rivastigmine; Tetrahydroaminoacridine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; METRIFONATE; RIVASTIGMINE; TACRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME KINETICS; FEMALE; MALE; NERVE CELL; NEUROANATOMY; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SWINE;

ACETYLCHOLINE; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ENZYME ACTIVATION; FEMALE; HEART; KINETICS; MALE; MODELS, ANIMAL; NEURONS; SUBSTRATE SPECIFICITY; SWINE; SYNAPTIC TRANSMISSION;

EID: 3042758854     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.05.002     Document Type: Article

References (46)

1. Aharon-Peretz J., Harel T., Revach M., Ben-Haim S.A. Increased sympathetic and decreased parasympathetic cardiac innervation in patients with Alzheimer's disease. Arch. Neurol. 49:1992;919-922
2. Algotsson A., Vitanen M., Winblad B., Solders G. Autonomic dysfunction in Alzheimer's disease. Acta Neurol. Scand. 91:1995;14-18
3. Armour J.A. Anatomy and function of the intrathoracic neurons regulating the mammalian heart. Reflex Control of the Circulation. 1991;1-37 CRC Press, Boca Raton, FL
4. Armour J.A., Hopkins D.A. Activity of in vivo canine ventricular neurons. Am. J. Physiol. 258:1990;H326-H336
5. Arora R.C., Waldman M., Hopkins D.A., Armour J.A. Porcine intrinsic cardiac ganglia. Anat. Rec. 271A:2003;249-258
6. Bartus R.T., Dean R.L.I., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417
7. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190
8. Darvesh S., Hopkins D.A. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J. Comp. Neurol. 463:2003;25-43
9. Darvesh S., Grantham D.L., Hopkins D.A. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J. Comp. Neurol. 393:1998;374-390
10. Darvesh S., MacDonald S.E., Losier A.M., Martin E., Hopkins D.A., Armour J.A. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. J. Auton. Nerv. Syst. 71:1998;75-84
11. Darvesh S., Arora R.C., Hopkins D.A., Armour J.A. Cholinesterase inhibitor effects on the intrinsic cardiac nervous system and cardiodynamics. Neurosci. Abstr. 26:2000;2289
12. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev., Neurosci. 4:2003;131-138
13. Darvesh S., Walsh R., Kumar R., Caines A., Roberts S., Magee D., Rockwood K., Martin E. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzeimer Dis. Assoc. Disord. 17:2003;117-126
14. Doody R.S. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J. Clin. Psychiatry. 64:2003;11-17
15. Ellman G.L., Courtney K.D., Andres V.J., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95
16. Elmstahl S., Petersson M., Lilja B., Samuelsson S.M., Rosen I., Bjuno L. Autonomic cardiovascular responses to tilting in patients with Alzheimer's disease and in healthy women. Age Ageing. 21:1992;301-307
17. Enz A., Florsheim P. Cholinesterase inhibitors: an overview of their mechanism of action. Alzheimer's disease. From Molecular Biology to Therapy. 1996;211-215 Birkhauser, Boston, MA
18. Enz A., Amstutz R., Boddeke H., Gmelin G., Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 98:1993;431-438
19. Foreman R.D., Blair R.W., Holmes H.R., Armour J.A. Correlation of ventricular mechanosensory neurite activity with myocardial sensory field deformation. Am. J. Physiol. 276:1999;R979-R989
20. Franceschi M., Ferini-Strambi L., Minicucci F., Sferrazza-Papa A., Smirne S. Signs of cardiac autonomic dysfunction during sleep in patients with Alzheimer's disease. Gerontology. 32:1986;327-334
21. Gagliardi M., Randall W.C., Bieger D., Wurster R.D., Hopkins D.A., Armour J.A. Activity of neurons in the in situ canine heart. Am. J. Physiol. 225:1988;H789-H800
22. Giacobini E. From molecular structure to Alzheimer therapy. Jpn. J. Pharmacol. 74:1997;225-241
23. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. 2000;181-226 Martin Dunitz Ltd. London, UK
24. Giubilei F., Strano S., Imbimbo B.P., Tisei P., Calcagnini G., Lino S., Frontoni M., Santini M., Fieschi C. Cardiac autonomic dysfunction in patients with Alzheimer's disease: possible pathogenetic mechanisms. Alzheimer Dis. Assoc. Disord. 12:1998;356-361
25. Greig N.H., De Micheli E., Holloway H.W., Yu Q.S., Utsuki T., Perry T.A., Brossi A., Ingram D.K., Deutsch J., Lahiri D.K., Soncrant T.T. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol. Scand. 176:2000;74-84
26. Greig N.H., Utsuki T., Yu Q., Zhu X., Holloway H.W., Perry T., Lee B., Ingram D.K., Lahiri D.K. A new therapeutic target in Alzheimer's disease: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 17:2001;159-165
27. Grunwald J., Marcus D., Papier Y., Raveh L., Pittel Z., Ashani Y. Large-scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. J. Biochem. Biophys. Methods. 34:1997;123-135
28. Grutzendler J., Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 61:2001;41-52
29. Hodgson A.J., Chubb I.W. Isolation of the secretory form of soluble acetylcholinesterase by using affinity chromatography on edrophonium-sepharose. J. Neurochem. 41:1983;654-662
30. Huang M.H., Smith F.M., Armour J.A. Modulation of in situ canine intrinsic cardiac neuronal activity by nicotinic, muscarinic and β-adrenergic agonists. Am. J. Physiol. 265:1993;R659-R669
31. Ikari H., Spangler E.L., Greig N.H., Pei X.F., Brossi A., Speer D., Patel N., Ingram D.K. Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. NeuroReport. 6:1995;481-484
32. Karnovsky M.J., Roots L.A. "Direct-coloring" thiocholine method for cholinesterases. J. Histochem. Cytochem. 12:1964;219-232
33. Krall W.J., Sramek J.J., Cutler N.R. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann. Pharmacother. 33:1999;441-450
34. Nordgren I., Bergstrom M., Holmsted B., Sandoz M. Transformation and action of metrifonate. Arch. Toxicol. 41:1978;31-41
35. Norel X., Angrisani M., Labat C., Gorenne I., Dulmet E., Rossi F., Brink C. Degradation of acetylcholine in human airways: role of butyrylcholinesterase. Br. J. Pharmacol. 109:1993;914-919
36. Priola D.V., Spurgeon H.A., Geis W.P. The intrinsic innervation of the canine heart: a functional study. Circ. Res. 40:1977;50-56
37. Reiner E., Radić Z. Mechanism of action of cholinesterase inhibitors. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. 2000;103-119 Martin Dunitz Ltd. London, UK
38. Rockwood K., Darvesh S. Cholinergic drugs for Alzheimer's disease. Gray J. Drug Advances. vol. 1:2003;159-177 Remedica Publishing, London, UK
39. Segel I.H. Biochemical Calculations. 1976;Wiley, New York
40. Silver A. The Biology of Cholinesterases. 1974;Elsevier, Amsterdam
41. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5, 6-dimethoxy-1-oxoindan-2-yl) methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38:1995;4821-4829
42. Tago H., Maeda T., McGeer P.L., Kimura H. Butyrylcholinesterase-rich neurons in rat brain demonstrated by a sensitive histochemical method. J. Comp. Neurol. 325:1992;301-312
43. Vitiello B., Veith R.C., Molchan S.E., Martinez R.A., Lawlor B.A., Radcliffe J., Hill J.L., Sunderland T. Autonomic dysfunction in patients with dementia of the Alzheimer type. Biol. Psychiatry. 34:1993;428-433
44. Wang S.J., Liao K.K., Fuh J.L., Lin K.N., Wu Z.A., Liu C.Y., Liu H.C. Cardiovascular autonomic functions in Alzheimer's disease. Age Ageing. 23:1994;400-404
45. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence of selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10:1981;122-126
46. Yuan B.X., Ardell J.L., Hopkins D.A., Armour J.A. Differential cardiac responses induced by nicotinic sensitive canine atrial and ventricular neurons. Cardiovasc. Res. 27:1993;760-769